Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: Safety, effectiveness, and impact on lipid profile

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Santos, José R ^a,b   Moltó, José ^a,b   Llibre, Josep M ^a,b   Negredo, Eugenia ^a,b   Bravo, Isabel ^a   Ornelas, Arelly ^a,c   Clotet, Bonaventura ^a,d   Paredes, Roger ^a,d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d IrsiCaixa Foundation   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RITONAVIR; SULFONAMIDE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; JAUNDICE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROTOXICITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; DIET RESTRICTION; DRUG EFFECT; GENETICS; GENOTYPING TECHNIQUE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID METABOLISM; METABOLISM; MIDDLE AGED; PATHOGENICITY; SAFETY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; COHORT STUDIES; FASTING; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITONAVIR; SAFETY; SULFONAMIDES;

EID: 84861535973     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037442     Document Type: Article

References (20)

1. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-33.
2. Brinkman K, Hofstede H, Burger DM, Smeitink JA, Koopmans PP, (1998) Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12: 1735-44.
3. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, et al. (2010) Antiretroviral Treatment of Adult HIV Infection; 2010 Recommendations of the International AIDS Society-USA Panel. JAMA 304: 321-33.
4. European AIDS Clinical Society (EACS). Guidelines. Clinical management and treatment of HIV-infected adults in Europe. April 2011, version 5-4. Available: http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected Adults.pdf. Accessed: 13 May 2011.
5. Shen L, Peterson S, Sedaghat A, McMahon MA, Callender M, et al. (2008) Dose-response curve slope set class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14: 762-766.
6. Boffito M, Miralles D, Hill A, (2008) Pharmacokinetics, efficacy and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and experienced patients. HIV Clin Trials 9: 418-427.
7. Arribas J, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, et al. (2010) The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 24: 223-230.
8. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, et al. (2010) Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 24: 2365-74.
9. Gazzard B, Hill A, Anceau A, (2011) Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy 9: 217-23.
10. Gutmann Ch, Opravil M, Fux C, Fux C, Hirschel B, et al. (2010) Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 24: 2347-2354.
11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf. Accessed: 20 June 2011.
12. Clumeck N, Rieger A, Banhegyi D, Schmidt W, Hill A, et al. (2011) 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. J Antimicrob Chemother 66: 1878-85.
13. Valantin MA, Flandre P, Kolta S, Duvivier C, Algarte-Genin M, et al. (2010) Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial: Results at 48 weeks. 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010 San Francisco poster O-262.
14. Flandre P, Van PN, Cohen-Codar I, Valantin MA, et al. (2011) Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial. Curr HIV Res 9: 31-9.
15. Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, et al. (2010) A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 24: 1777-1785.
16. Valantin MA, Bittar R, de Truchis P, Bollens D, Slama L, et al. (2010) Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother 65: 556-61.
17. Campo R, De Jesus E, Khanlou H, Wang H, Dau L, et al. (2011) SWIFT Study: Switching from lamivudine/abacavir (3TC/ABC) to emtricitabine/tenofovir DF (FTC/TDF) based regimen improves lipid parameters while maintaining virologic suppression. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20th, 2011 Chicago poster H2-786.
18. Chen JY, Wang JH, Lin CY, Chen PF, Tseng PL, et al. (2010) Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B and C strains independently. J Gastroenterol Hepatol 25: 1763-8.
19. Bedimo R, Ghurani R, Nsuami M, Turner D, Kvanli MB, et al. (2006) Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. HIV Med 7: 530-6.
20. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, et al. (2010) Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 11: 462-8.